Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JUR-003 in Metastatic Prostate Cancer
NCT07824349Phase 1Recruiting
- Sponsor
- Juri Biosciences
- Start
- Oct 2026
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
Phase 1, open-label trial of EM1031 in metastatic castration-resistant prostate cancer (mCRPC) and prostate cancer (PCa) (2 arms), sponsored by Juri Biosciences. Primary endpoints: Safety and Tolerability at 2 years, Recommended Dose for Expansion at 1 year and 1 more. Started Oct 2026; status: recruiting.
02
Drugs
EM1031
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07824349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07824349.